Novavax (NVAX) : Alden Global Capital reduced its stake in Novavax by 40.0% during the most recent quarter end. The investment management company now holds a total of 600,000 shares of Novavax which is valued at $4,224,000 after selling 400,000 shares in Novavax , the firm said in a disclosure report filed with the SEC on Aug 15, 2016.Novavax makes up approximately 4.36% of Alden Global Capital’s portfolio.
Other Hedge Funds, Including , Bluecrest Capital Management Ltd added NVAX to its portfolio by purchasing 25,508 company shares during the most recent quarter which is valued at $179,576. Novavax makes up approx 0.01% of Bluecrest Capital Management Ltd’s portfolio.Proshare Advisors boosted its stake in NVAX in the latest quarter, The investment management firm added 4,833 additional shares and now holds a total of 243,571 shares of Novavax which is valued at $1,714,740. Novavax makes up approx 0.02% of Proshare Advisors’s portfolio.Teachers Advisors Inc boosted its stake in NVAX in the latest quarter, The investment management firm added 18,192 additional shares and now holds a total of 687,375 shares of Novavax which is valued at $4,839,120. Novavax makes up approx 0.01% of Teachers Advisors Inc’s portfolio.Vanguard Group Inc boosted its stake in NVAX in the latest quarter, The investment management firm added 1,385,637 additional shares and now holds a total of 19,935,014 shares of Novavax which is valued at $140,342,499. Novavax makes up approx 0.01% of Vanguard Group Inc’s portfolio.Blackrock Japan Ltd reduced its stake in NVAX by selling 1,915 shares or 11.9% in the most recent quarter. The Hedge Fund company now holds 14,181 shares of NVAX which is valued at $99,834.
Novavax closed down -0.02 points or -0.29% at $6.82 with 27,66,439 shares getting traded on Thursday. Post opening the session at $6.85, the shares hit an intraday low of $6.705 and an intraday high of $6.89 and the price fluctuated in this range throughout the day.Shares ended Thursday session in Red.
On the company’s financial health, Novavax reported $-0.29 EPS for the quarter, missing the analyst consensus estimate by $ -0.04 based on the information available during the earnings call on Aug 9, 2016. Analyst had a consensus of $-0.25. The company had revenue of $2.50 million for the quarter, compared to analysts expectations of $8.10 million. The company’s revenue was down -82.1 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $-0.08 EPS.
Novavax Inc. (Novavax) is a clinical-stage vaccine company engaged in the discovery development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company through its recombinant nanoparticle vaccine technology produces vaccine candidates to respond to both known and newly emerging diseases. The Company’s product pipeline focuses on a variety of infectious diseases with vaccine candidates in clinical development for respiratory syncytial virus (RSV) seasonal influenza pandemic influenza and the Ebola virus (EBOV). The Company’s lead adjuvant for human applications Matrix-M is in a Phase I/II clinical trial for pandemic influenza H7N9 vaccine candidate. The Company is also testing Matrix-M in conjunction with its EBOV vaccine candidate in a Phase I clinical trial. The Company is developing additional pre-clinical stage programs in a variety of infectious diseases including Middle East respiratory syndrome (MERS).